Patents by Inventor Kap-Sun Yeung

Kap-Sun Yeung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11046675
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various pp diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 29, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Denis R. St. Laurent, Jeffrey Lee Romine, Paul Michael Scola
  • Publication number: 20210094932
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: February 28, 2019
    Publication date: April 1, 2021
    Inventors: Kap-Sun YEUNG, Denis R. ST. LAURENT, David R. LANGLEY, Paul Michael SCOLA
  • Publication number: 20210053972
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: January 23, 2019
    Publication date: February 25, 2021
    Inventors: Kap-Sun YEUNG, Juliang ZHU, Paul Michael SCOLA
  • Publication number: 20210023098
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, ?2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: October 13, 2020
    Publication date: January 28, 2021
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Patent number: 10882844
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 5, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, Li-Qiang Sun, David R. Langley, Denis R. St. Laurent, Paul M. Scola
  • Publication number: 20200291002
    Abstract: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: March 17, 2017
    Publication date: September 17, 2020
    Inventors: Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Prakash Anjanappa, Kumaravel Selvakumar, Samayamunthula Venkata Satya Arun Gupta
  • Patent number: 10745382
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 18, 2020
    Assignee: bristol-myers squibb company
    Inventors: Kap-Sun Yeung, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
  • Publication number: 20200181125
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various pp diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 26, 2018
    Publication date: June 11, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kap-Sun YEUNG, Denis R. ST. LAURENT, Jeffrey Lee ROMINE, Paul Michael SCOLA
  • Patent number: 10590105
    Abstract: The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: March 17, 2020
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, Zhaoxing Meng, Paul Michael Scola
  • Publication number: 20200046743
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: October 22, 2019
    Publication date: February 13, 2020
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Patent number: 10538555
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: January 21, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Kevin W. Gillman, Qian Zhao, Katharine A. Grant-Young, Paul Michael Scola, Lyndon A. M. Cornelius
  • Publication number: 20190352280
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 19, 2017
    Publication date: November 21, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kap-Sun YEUNG, Katharine A. GRANT-YOUNG, Li-Qiang SUN, David R. LANGLEY, Denis R. ST. LAURENT, Paul M. SCOLA
  • Publication number: 20190185450
    Abstract: The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: July 5, 2017
    Publication date: June 20, 2019
    Inventors: Kap-Sun YEUNG, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, Zhaoxing Meng, Paul Michael Scola
  • Publication number: 20190111066
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: November 14, 2018
    Publication date: April 18, 2019
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Patent number: 10150747
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: December 11, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Prakash Anjanappa, Samayamunthula Venkata Satya Arun Kumar Gupta
  • Patent number: 10144706
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: December 4, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
  • Patent number: 10143746
    Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: December 4, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael Scola
  • Publication number: 20180057455
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 1, 2018
    Inventors: KAP-SUN YEUNG, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
  • Patent number: 9879046
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: January 30, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Patrick C. Reid, Paul Michael Scola
  • Publication number: 20180022723
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: February 19, 2016
    Publication date: January 25, 2018
    Inventors: Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Prakash Anjanapa, Samayamunthula Venkata Satya Arun Kumar